Roberto Cacciaglia
Overview
Explore the profile of Roberto Cacciaglia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomasini M, Loche A, Cacciaglia R, Ferraro L, Beggiato S
Pharmacol Rep
. 2024 Aug;
76(5):1174-1183.
PMID: 39088104
Background: - Alcohol-induced pro-inflammatory activation might influence cellular and synaptic pathology, thus contributing to the behavioral phenotypes associated with alcohol use disorders. In the present study, the possible anti-inflammatory properties...
2.
Guiraud J, Addolorato G, Antonelli M, Aubin H, de Bejczy A, Benyamina A, et al.
J Psychopharmacol
. 2022 Jul;
36(10):1136-1145.
PMID: 35796481
Background: Sodium oxybate (SMO) has been shown to be effective in the maintenance of abstinence (MoA) in alcohol-dependent patients in a series of small randomized controlled trials (RCTs). These results...
3.
Haass-Koffler C, Perciballi R, Magill M, Loche A, Cacciaglia R, Leggio L, et al.
Psychopharmacology (Berl)
. 2021 Nov;
239(1):35-46.
PMID: 34731268
Rationale: Previous work suggests that GET 73, a novel compound with putative activity on the metabotropic glutamate receptor subtype 5 (mGluR5), may represent a novel pharmacological treatment for alcohol use...
4.
Beggiato S, Borelli A, Tomasini M, Castelli M, Pintori N, Cacciaglia R, et al.
Front Pharmacol
. 2018 Apr;
9:327.
PMID: 29674969
The present study was aimed to further characterize the pharmacological profile of N-[4-(trifluoromethyl) benzyl]-4-methoxybutyramide (GET73), a putative negative allosteric modulator (NAM) of metabotropic glutamate subtype 5 receptor (mGluR5) under development...
5.
Haass-Koffler C, Goodyear K, Loche A, Long V, Lobina C, Tran H, et al.
J Psychopharmacol
. 2018 Jan;
32(2):163-173.
PMID: 29361897
Preclinical work suggests that GET 73 (N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide), a novel metabotropic glutamate receptor subtype 5 negative allosteric modulator, may represent a novel pharmacological treatment for alcohol use disorder. Two independent experiments...
6.
Haass-Koffler C, Goodyear K, Long V, Tran H, Loche A, Cacciaglia R, et al.
Data Brief
. 2017 Dec;
15:407-413.
PMID: 29214202
The data in this article outline the methods used for the administration of GET 73 in the first time-in-human manuscript entitled "Phase I randomized clinical trial for the safety, tolerability...
7.
Haass-Koffler C, Goodyear K, Long V, Tran H, Loche A, Cacciaglia R, et al.
Eur J Pharm Sci
. 2017 Aug;
109:78-85.
PMID: 28778464
Preclinical work suggests that the metabotropic glutamate receptor subtype 5 (mGlu5) may represent a novel target to treat neuropsychiatric disorders, including alcohol use disorder and obesity. The goal of this...
8.
Tomasini M, Borelli A, Beggiato S, Tanganelli S, Loche A, Cacciaglia R, et al.
Alcohol Alcohol
. 2015 Aug;
51(2):128-35.
PMID: 26271115
Aims: N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide (GET73) may be considered a promising therapeutic agent for the treatment of alcohol use disorders. The compound displayed anti-alcohol and anxiolytic properties in rat. In the...
9.
Beggiato S, OConnor W, Tomasini M, Antonelli T, Loche A, Tanganelli S, et al.
Synapse
. 2013 Apr;
67(10):678-91.
PMID: 23564259
N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide (GET73) is a newly synthesized compound displaying anti-alcohol and anxiolytic properties. In light of the importance of the hippocampal CA1 subregion in alcohol addiction and anxiety-like behaviors-this...
10.
Loche A, Simonetti F, Lobina C, Carai M, Colombo G, Castelli M, et al.
Front Psychiatry
. 2012 Feb;
3:8.
PMID: 22347868
N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide (GET73) is a newly synthesized compound structurally related to the clinically used, alcohol-substituting agent, gamma-hydroxybutyric acid (GHB). The present study was designed to assess whether GET73 may share with...